So this signals that we remain in a solid financial position, and we are actually at the same leverage as last year, even though we have made investments in strategic acquisitions since then, which has amounted to approximately 4.2 billion SEK. Thanks, Agneta. When it comes to our strategy for profitable growth, there are some key enablers that we focus on. And part of this is about increasing the share from recurring revenue.
Accelerating the share of sales from high-margin products like ECLS and also Beta Bags in our Sterile Transfer product category.
And this all should be supported by solid and effective quality processes.
So these improvements should, of course, be achieved through responsible leverage and an attractive long-term return on invested capital. We clearly see that we're delivering according to our plan in this respect, as all those KPIs are trending in the right direction.
You can see that sales from recurring revenue are now at 65%, and the high-margin products currently make up about two-thirds of our sales. When it comes to quality, the number of field actions in relation to sales has also decreased significantly, which is a positive leading indicator for the hard work that's been ongoing for quite some time. With this, we can move over to page eight, please.
So in addition to our quarterly performance, I wanted to spend some time talking about what's going on in the world right now and how we navigate this.
There's certainly a lot of dynamics in the market related to the geopolitical uncertainty that we're seeing now. So here are three examples of areas offering both some challenges and opportunities for us when it comes to tariffs. The current situation with increased trade barriers and higher tariffs is, we believe, unfortunate. We're a global company with a global footprint, which naturally mitigates this to some extent. And I'll touch on that a little bit more in the coming slides here. When it comes to budgets, there is a trend for more investment in defense and the civil sector, where we also hope to be able to contribute.
Germany's plan is valued at €500 billion.
Plan is, uh, one concrete example of this.
Furthermore, the ambition of the healthcare sector to become more productive aligns well with the strength of our products and service portfolio. And then specifically in the US, we have lately seen some pause in research funding impacting our life science sales to customers within this business area.
On the other hand, we do note as well that several big pharma companies are preparing for US expansion, and that's something that we are well positioned to support them with.
Uh, when it comes to some of the structural changes at the FDA that have been in the news, this has not yet resulted in any negative impact for us. We continue to have a constructive dialogue on a weekly basis. So the way we address these dynamics is, for example, by continuing to have a close dialogue with our customers and the authorities, who are stakeholders in our business. We will continue to make price adjustments if needed and where possible.
So, this is ongoing work, something that we've been working on for many years. And that needs to be accelerated a bit now.
And we will also be agile when it comes to the allocation of volumes to secure profitability throughout our operations.
We can then move to page number nine and just wanted to share an overview of our global footprint.
So we have, I would say, a geographically well-diversified production footprint. We have 25 production sites spread over nine countries.
So on the slide here, you can see an overview of our footprint broken down by product category. So in the US and EU, we produce for all business areas.
While the Chinese site in Suzhou supports Acute Care Therapies and Surgical Workflows.
Let's then move to page number ten please.
Um, and when it comes to our sales in the US, about 60% of everything that we sell in the US is also produced domestically. Uh, and you can see on the slide here an overview per macro region. So when translating this into sales, you get 60% of sales in the US produced in the US that I just mentioned. Still a lot of uncertainty and changing dynamics related to the tariff situation.
So we will not comment on any potential financial impacts of this yet. But hopefully the view shared here should bring some clarity when it comes to our exposure. So with that, let's move to page 11 please.
And the outlook for the year.
So the outlook for 2025 is unchanged.
Uh, we remain with our expectation for organic net sales growth to be in the range of 2 to 5% compared to last year's sales.
And this outlook then assumes sales contribution from the intended phase-out of the Surgical Perfusion business at about two-thirds of the 2024 figures, which equates to roughly 300 million SEK. In addition, we expect recent acquisitions to contribute about 2% to growth this year. We can then move to page 12.
Please. So just to summarize some of the key takeaways for the quarter, we've delivered a very strong performance when it comes to net sales. Uh, and uh, also with improved margins.
Our leverage continues to decrease, now reaching the same level as before the acquisition of Paragonix.
And our financial position overall remains very solid.
We stand by our outlook for 2025, which will be a guide for organic net sales growth of 2 to 5%. Our priorities for 2025 remain unchanged. It's about addressing the remaining challenges in Acute Care Therapies when it comes to our quality.
It's about sustainable productivity improvement and cost consciousness when navigating the geopolitical uncertainty that's been with us for a while now.
And it's about continuing to create value for our customers.
So with that summary, I open up for questions.
We stand by our outlook for 2025, which will guide an organic net sales growth of 2 to 5%.